Drug Trial Radar · NCT00434993
Drug Study of Albuterol to Treat Acute Lung Injury
Last checked: Nov 20, 2026Latest source record: Feb 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
282
Actual
Start
Aug 2007
Primary completion
Sep 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- First posted
- Feb 14, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute Respiratory Distress Syndrome (ARDS) and a lesser condition that occurs prior to ARDS, Acute Lung Injury (ALI), are medical conditions that occur when there is severe inflammation and increased fluids (edema) in both lungs, making it hard for the lungs to function properly. Patients with these conditions require treatment that includes the use of a breathing machine (ventilator). The purpose of this study is to find out whether giving albuterol (a drug commonly used in asthmatics) or not giving albuterol to patients with ALI or ARDS makes a difference in how long it takes for a patient to be able to breath without the ventilator.
Conditions
- Respiratory Distress Syndrome, Adult
Interventions
Albuterol SulfateDrug
Albuterol sulfate, USP, solution for inhalation will be diluted as follows: * The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution. * The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution. A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
Mini-Bronchoalveolar Lavage (BAL)Procedure
The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
PlaceboDrug
Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative. A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle). The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Ventilator Free Days (VFD)Time frame: Determined 28 days after a subject entered the study
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
University of San Francisco-Fresno Medical Center
Fresno, California
University of California, Davis Medical Center
Sacramento, California
UCSF-Moffitt Hospital
San Francisco, California
UCSF-San Francisco General Hospital
San Francisco, California
Centura St. Anthony Central Hospital
Denver, Colorado
Denver Health Medical Center
Denver, Colorado
Rose Medical Center
Denver, Colorado
University of Colorado Health Sciences Center
Denver, Colorado
Washington Hospital Center
Washington D.C., District of Columbia
Baton Rouge General Hospital-Blue Bonnet
Baton Rouge, Louisiana
Baton Rouge General Hospital-Midcity
Baton Rouge, Louisiana
Earl K. Long Medical Center
Baton Rouge, Louisiana
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana
Medical Center of Louisiana
New Orleans, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana
Tulane University Health Sciences Center
New Orleans, Louisiana
Baltimore VA Medical Center
Baltimore, Maryland
Johns Hopkins Bayview Medical Center
Baltimore, Maryland
Johns Hopkins Hospital
Baltimore, Maryland
University of Maryland Shock Trauma Center
Baltimore, Maryland
Baystate Medical Center
Springfield, Massachusetts
Rochester Methodist Hospital
Rochester, Minnesota
St. Mary's Hospital, Mayo Clinic
Rochester, Minnesota
University of North Carolina
Chapel Hill, North Carolina
Duke University Medical Center
Durham, North Carolina
Durham Regional Medical Center
Durham, North Carolina
Moses Cone Health System
Greensboro, North Carolina
Wesley Long Community Hospital
Greensboro, North Carolina
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
MetroHealth Medical Center
Cleveland, Ohio
University Hospitals of Cleveland
Cleveland, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
McKay-Dee Hospital
Ogden, Utah
Utah Valley Regional Medical Center
Provo, Utah
LDS Hospital
Salt Lake City, Utah
University of Virginia Medical Center
Charlottesville, Virginia
Harborview Medical Center
Seattle, Washington
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.